Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

Please provide your email address to receive an email when new articles are posted on . In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

Scientists discovered which tumor cells resist treatment and why. By characterizing B-cells' developmental stages, they designed and tested a drug combination to effectively treat resistant B-cell ...

Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...

Greater understanding of the potential role played by B cells in autoimmune disease has spurred an interest in targeting B cells therapeutically. Greater understanding of the potential role played by ...

In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...